COLL vs EQIX · P/E 17, rev $181.9M vs P/E 79, rev $9.22B
Collegium Pharmaceutical Inc (COLL) versus Equinix Inc (EQIX) — a side-by-side from cached financials, not a winner call.
Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Equinix Inc (EQIX) is a reit - specialty company listed on US.
Latest reported COLL revenue for 2024-12-31 was $181.9M. Net income was $69.2M. Revenue was up 14.2% from 2024-09-30 to 2024-12-31. COLL currently screens at market cap $1.12B and trailing P/E 16.8.
Latest reported EQIX revenue for 2025-12-31 was $9.22B. Net income was $1.35B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
COLL currently screens at market cap $1.12B and trailing P/E 16.8. EQIX currently screens at market cap $74.23B and trailing P/E 79.4.
Not investment advice. Open the COLL and EQIX stock pages for the full models.
Not investment advice.